Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hikma PharmaceuticalsHKMPF -2.01%82 5-Year Yield-on-Cost % is 7.61 as of Jul. 19, 2026, which is 100% above its 10-year median of 3.81. GuruFocus rates HKMPF with a GF Score™ of 82/100 and a GF Value™ of $28.54 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 513 Drug Manufacturers companies, Hikma Pharmaceuticals ranks better than 84.41% on this metric.
Hikma Pharmaceuticals's yield on cost for the quarter that ended in Dec. 2025 was 7.61.
The historical rank and industry rank for Hikma Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:
HKMPF'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.25 Med: 3.81 Max: 10.01
Current: 7.61
During the past 13 years, Hikma Pharmaceuticals's highest Yield on Cost was 10.01. The lowest was 1.25. And the median was 3.81.
HKMPF's 5-Year Yield-on-Cost % is ranked better than 84.41% of 513
companies
in the Drug Manufacturers industry
Industry Median: 2.29
vs HKMPF: 7.61
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Hikma Pharmaceuticals 5-Year Yield-on-Cost % Related Terms
HKMPF vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikma Pharmaceuticals 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Hikma Pharmaceuticals's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Hikma Pharmaceuticals (HKMPF) has a 5-Year Yield-on-Cost % of 7.61 as of Jul. 19, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Hikma Pharmaceuticals and its competitors. This is 100% above median its historical median of 3.81. Over the past decade, Hikma Pharmaceuticals' 5-Year Yield-on-Cost % has ranged from 1.25 to 10.01. According to the industry distribution chart, Hikma Pharmaceuticals ranks #80 out of 513 companies in the Drug Manufacturers industry, placing it in the top 15.6%.
Is Hikma Pharmaceuticals' 5-Year Yield-on-Cost % too high?
Hikma Pharmaceuticals' current 5-Year Yield-on-Cost % of 7.61 is 100% above median its 10-year median of 3.81. Over the past 10 years, this metric has ranged from a low of 1.25 to a high of 10.01. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.29. Hikma Pharmaceuticals' value of 7.61 is 232.3% above this industry median. Based on the distribution chart, Hikma Pharmaceuticals ranks #80 out of 513 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hikma Pharmaceuticals has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hikma Pharmaceuticals ranks #80 out of 513 companies for 5-Year Yield-on-Cost %. This places Hikma Pharmaceuticals in the top 16% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.29. Hikma Pharmaceuticals' value of 7.61 is 232.3% above this benchmark. Historically, Hikma Pharmaceuticals' own 5-Year Yield-on-Cost % has ranged from 1.25 to 10.01 over the past decade. While the company's 10-year median is 3.81 vs. the industry median of 2.29, Hikma Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.29, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hikma Pharmaceuticals's current 5-Year Yield-on-Cost % of 7.61 is 232.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Hikma Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hikma Pharmaceuticals's current 5-Year Yield-on-Cost % is 7.61, which is 100% above median its own 10-year median of 3.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPF) is currently considered Modestly Undervalued. The stock's GF Value™ is $28.54, compared to a current price of $21.26 — trading 25.5% below its estimated fair value. The current 5-Year Yield-on-Cost % is 7.61, which is 100% above median its 10-year median of 3.81 and 232.3% above the Drug Manufacturers industry median of 2.29. Hikma Pharmaceuticals' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPF), the current 5-Year Yield-on-Cost % is 7.61 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hikma Pharmaceuticals (HKMPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued.
The current stock price of $21.26 is trading 25.5% below its estimated GF Value™ of $28.54.
GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for HKMPF:
5-Year Yield-on-Cost %: 7.61 (100% above median its 10-year median of 3.81)
GF Value™: $28.54 vs. price of $21.26 (25.5% below fair value)
Industry Position: 232.3% above the Drug Manufacturers median (#80 of 513)
No single metric tells the full story. See the HKMPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
82GF Score
Get the complete analysis for HKMPF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKMPF has been successfully added to your 
